Pragmatic issues in biomarker evaluation for targeted therapies in cancer.

Détails

ID Serval
serval:BIB_F3AC109D0B51
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Pragmatic issues in biomarker evaluation for targeted therapies in cancer.
Périodique
Nature Reviews. Clinical Oncology
Auteur(s)
de Gramont A., Watson S., Ellis L.M., Rodón J., Tabernero J., de Gramont A., Hamilton S.R.
ISSN
1759-4782 (Electronic)
ISSN-L
1759-4774
Statut éditorial
Publié
Date de publication
2015
Peer-reviewed
Oui
Volume
12
Numéro
4
Pages
197-212
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; ReviewPublication Status: ppublish
Résumé
Predictive biomarkers are becoming increasingly important tools in drug development and clinical research. The importance of using both guidelines for specimen acquisition and analytical methods for biomarker measurements that are standardized has become recognized widely as an important issue, which must be addressed in order to provide high-quality, validated assays. Herein, we review the major challenges in biomarker validation processes, including pre-analytical (sample-related), analytical, and post-analytical (data-related) aspects of assay development. Recommendations for improving biomarker assay development and method validation are proposed to facilitate the use of predictive biomarkers in clinical trials and the practice of oncology.
Mots-clé
Antineoplastic Agents/therapeutic use, Biomarkers, Tumor/metabolism, Drug Monitoring/methods, Humans, Molecular Targeted Therapy, Neoplasms/drug therapy, Prognosis, Reproducibility of Results
Pubmed
Web of science
Création de la notice
18/10/2016 16:13
Dernière modification de la notice
03/03/2018 22:42
Données d'usage